Telescope Innovations (TELI) Q3 2024 earnings summary

Executive summary

• Year-to-date revenues exceeded the entire previous fiscal year, reaching over $3.4 million as of Q3 2024.

• Q3 2024 revenues were $1.2 million, up from $1.01 million in the same quarter last year.

• Increased sales of the DirectInject-LC product and higher customer engagement through conferences and demonstrations contributed to growth.

Financial highlights

• Revenues for the fiscal quarter were $1,224,351, with year-to-date revenues at $3,415,408, both higher than the prior year.

• Expenses for the quarter were $1,424,650, and $3,941,921 year-to-date, up from $945,152 and $2,531,466 respectively in the prior year.

• Positive cash flow from operating activities of $40,023 year-to-date, compared to negative $1,745,535 in the prior year.

Segment performance

• DirectInject-LC product sales saw an uptick, driving revenue growth in the quarter.